MAPT and Alzheimer disease: By simultaneously detecting t-tau/Aβ1-42, p-tau/Aβ1-42, and Aβ1-42/Aβ1-40 in clinical plasma samples, the fabricated sensor could differentiate patients with AD from healthy controls.